Sumeet Bhatia, MD
Medical Oncology · Indianapolis, INNPI 1922079474
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,797 of the $24,244 with a category attached, or 69.3%. It is spread thinly across 21 manufacturers, the largest accounting for just 23.2%.
Across 45 payments — averaging $538.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$6K
- Avyxa Pharma, LLC$4K
- AstraZeneca$3K
- TG Therapeutics, Inc.$3K
- Seagen Inc.$3K
- Incyte Corporation$3K
- plus $4K from 15 others
Across 8 payments — averaging $4198.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$14K
- Pfizer$10K
- AbbVie$10K
What the payments were for
- Consulting fees$16,79769%
- Speaking & faculty fees$3,20013%
- Travel & lodging$2,2079%
- Food & beverage$1,9408%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $5,633 |
| Avyxa Pharma, LLC | 7 | $3,789 |
| AstraZeneca | 2 | $2,846 |
| TG Therapeutics, Inc. | 2 | $2,810 |
| Seagen Inc. | 3 | $2,765 |
| Incyte Corporation | 1 | $2,580 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,235 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,200 |
| Adaptive Biotechnologies Corporation | 3 | $305 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $146 |
| Gilead(2 entities) | 2 | $134 |
| Regeneron Healthcare Solutions, Inc. | 1 | $131 |
| Intuitive Surgical | 1 | $131 |
| AbbVie | 3 | $124 |
| Edwards Lifesciences | 1 | $115 |
| Beigene USA, Inc. | 1 | $75 |
| Lilly USA, LLC | 1 | $73 |
| Tempus AI, Inc | 1 | $61 |
| Pfizer | 3 | $42 |
| GSK | 2 | $26 |
| Covidien LP | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,244 in reported general payments places this provider in the 80th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 76 | $1,475,019 |
| TagrissoOsimertinib Mesylate | 40 | $680,016 |
| PomalystPomalidomide | 29 | $577,265 |
| RevlimidLenalidomide | 33 | $577,212 |
| VerzenioAbemaciclib | 32 | $475,319 |
| BrukinsaZanubrutinib | 35 | $443,901 |
| VenclextaVenetoclax | 98 | $357,053 |
| AlecensaAlectinib Hcl | 19 | $331,916 |
| LenvimaLenvatinib Mesylate | 14 | $319,236 |
| BraftoviEncorafenib | 28 | $289,501 |
| SprycelDasatinib | 33 | $277,255 |
| MektoviBinimetinib | 20 | $273,125 |
| IbrancePalbociclib | 18 | $271,687 |
| JaypircaPirtobrutinib | 12 | $268,542 |
| XospataGilteritinib Fumarate | 12 | $254,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $146 | $1,475,01976 claims |
| AstraZenecaTagrisso, Calquence | $2,846 | $916,08757 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $1,235 | $854,52162 claims |
| Lilly USA, LLCVerzenio, Jaypirca | $73 | $743,86044 claims |
| PfizerIbrance, Bosulif, Vizimpro | $42 | $616,61347 claims |
| Beigene USA, Inc.Brukinsa | $75 | $443,90135 claims |
| AbbVieVenclexta | $124 | $357,05398 claims |
| Incyte CorporationJakafi | $2,580 | $182,11215 claims |
| Rigel Pharmaceuticals, Inc.Tavalisse | $1,200 | $175,81512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Indianapolis
- Natraj AmmakkanavarIndianapolis$129K
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
- Daniel SonnenburgIndianapolis$37K
- Michael SlaughterIndianapolis$17K
- Elsayed AlyIndianapolis$9K
- Anuj AgarwalaIndianapolis$8K
- Sead BeganovicIndianapolis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.